Literature DB >> 17482449

Laminin-332 (Laminin-5) is the major motility ligand for B cell chronic lymphocytic leukemia.

Paola Spessotto1, Antonella Zucchetto, Massimo Degan, Bruna Wasserman, Carla Danussi, Riccardo Bomben, Roberto Perris, Vincenzo Canzonieri, Oriano Radillo, Alfonso Colombatti, Valter Gattei.   

Abstract

Cell adhesion and motility are central aspects in the pathophysiology of B cell chronic lymphocytic leukemia (B-CLL), but the role of specific extracellular matrix proteins is still to be completely unveiled. Purified peripheral blood neoplastic cells of B-CLL patients migrated poorly on laminins-111,-411,-511, but showed pronounced motility on laminin (LM)-332 in a high percentage of cases. B-CLL cell motility on LM-332 was mediated by the alpha3beta1 integrin and was preferentially observed in cells carrying a mutated IgV(H) gene profile. Within normal lymph nodes, LM-332 was circumscribed around blood vessels and to areas corresponding to marginal zones, where it was deposited in a pattern reminiscent of reticular fibers. Conversely, in B-CLL involved lymph nodes, a positive LM-332 reticular mesh was diffusely evident, throughout the disrupted nodal architecture. In the present study we identified LM-332 as a crucial motility-promoting factor for B-CLL lymphocytes and as a potential constituent favoring the dissemination of B-CLL lymphocytes through vascular basement membranes and possibly lymph node compartments.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17482449     DOI: 10.1016/j.matbio.2007.04.003

Source DB:  PubMed          Journal:  Matrix Biol        ISSN: 0945-053X            Impact factor:   11.583


  5 in total

1.  The regulatory interaction of EVI1 with the TCL1A oncogene impacts cell survival and clinical outcome in CLL.

Authors:  E Vasyutina; J M Boucas; J Bloehdorn; C Aszyk; G Crispatzu; M Stiefelhagen; A Breuer; P Mayer; C Lengerke; H Döhner; D Beutner; A Rosenwald; S Stilgenbauer; M Hallek; A Benner; M Herling
Journal:  Leukemia       Date:  2015-05-04       Impact factor: 11.528

2.  ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression.

Authors:  Anna Guarini; Marilisa Marinelli; Simona Tavolaro; Emanuele Bellacchio; Monia Magliozzi; Sabina Chiaretti; Maria Stefania De Propris; Nadia Peragine; Simona Santangelo; Francesca Paoloni; Mauro Nanni; Ilaria Del Giudice; Francesca Romana Mauro; Isabella Torrente; Robin Foà
Journal:  Haematologica       Date:  2011-10-11       Impact factor: 9.941

3.  Cell Trafficking in Chronic Lymphocytic Leukemia.

Authors:  Matthew S Davids; Jan A Burger
Journal:  Open J Hematol       Date:  2012-02-21

Review 4.  Molecular Players in Hematologic Tumor Cell Trafficking.

Authors:  Javier Redondo-Muñoz; Angeles García-Pardo; Joaquin Teixidó
Journal:  Front Immunol       Date:  2019-02-06       Impact factor: 7.561

5.  A retinoic acid-dependent stroma-leukemia crosstalk promotes chronic lymphocytic leukemia progression.

Authors:  Diego Farinello; Monika Wozińska; Elisa Lenti; Luca Genovese; Silvia Bianchessi; Edoardo Migliori; Nicolò Sacchetti; Alessia di Lillo; Maria Teresa Sabrina Bertilaccio; Claudia de Lalla; Roberta Valsecchi; Sabrina Bascones Gleave; David Lligé; Cristina Scielzo; Laura Mauri; Maria Grazia Ciampa; Lydia Scarfò; Rosa Bernardi; Dejan Lazarevic; Blanca Gonzalez-Farre; Lucia Bongiovanni; Elias Campo; Andrea Cerutti; Maurilio Ponzoni; Linda Pattini; Federico Caligaris-Cappio; Paolo Ghia; Andrea Brendolan
Journal:  Nat Commun       Date:  2018-05-03       Impact factor: 14.919

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.